Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder -BOSTON, (GLOBE NEWSWIRE) -- X4 Pharmaceuticals ...
Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyRecently Completed Settlements with 3 Additional Generic ...
Milsaperidone is an active metabolite of iloperidone ...
ITF Therapeutics LLC, the U.S. rare disease affiliate of Italfarmaco, today announced that one oral and nine poster presentations have been accepted at the Muscular Dystrophy Association (MDA) ...
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment ...
Last month, Justin and Amy Miller packed their vehicles with three kids, two dogs, a pet bearded dragon, and whatever belongings they could fit, then drove 2,000 miles from Wisconsin to British ...
Health news moves fast, with new studies, findings, and regulatory updates changing the landscape daily. Insights from advocates and celebrities can also impact the public awareness of certain health ...
A unique study imaging brain activity in children born with upper limb difference – for example, one hand – has shown the amazing ability of the brain to adapt to compensate and support their daily ...
Eric Dane, the celebrated actor best known for his roles on "Grey's Anatomy" and "Euphoria" and who later in life became an ...